...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of human hypertension >Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group.
【24h】

Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group.

机译：在治疗原发性高血压中改善疗效并保持耐受性。非洛地平-美托洛尔联合片剂与依那普利单药治疗的比较。瑞典多中心集团。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this multicentre, double-blind, parallel-group study, 120 out-patients with mild to moderate primary hypertension were randomised, after a 4-week single-blind placebo run-in period, to a combination tablet of felodipine-metoprolol 5/50 mg (Logimax, Mobloc, Astra) once daily or enalapril 10 mg once daily. If blood pressure (BP) remained suboptimally controlled after 4 weeks (supine diastolic BP >90 mm Hg 24-h post dose), the dose was doubled for a further 4 weeks. After 8 weeks felodipine-metoprolol reduced supine BP significantly more than enalapril (19.7/12.0 mmHg and 11.1/7.2 mm Hg, respectively). The mean differences in change in BP between treatments were 8.6/4.8 mm Hg in favour of felodipine-metoprolol (P = 0.001/P <0.001). A statistically significant difference to the advantage of felodipine-metoprolol was also seen in standing BP. Even though the dose was increased in a larger proportion of patients in the enalapril group (61%) than in the felodipine-metoprolol group (40%), fewer enalapril-treated patients achieved adequate BP control (41% vs 63% on felodipine-metoprolol, P <0.05). Both treatments were well tolerated. Three patients treated with felodipine-metoprolol and four with enalapril discontinued treatment due to adverse events. A similar number of patients reported adverse events in each treatment group. In conclusion, a combination tablet of felodipine-metoprolol 5/50-10/100 mg once daily reduced BP more effectively than enalapril 10-20 mg once daily 24 h post dose. The result was expected, but a more important observation was that both treatments were tolerated to a similar degree. Obviously, a considerable BP reduction may be well tolerated, as was the main purpose to demonstrate in this study.
机译：在这项多中心，双盲，平行组研究中，将120名患有轻度至中度原发性高血压的门诊患者在4周单盲安慰剂磨合期后随机分配到非洛地平-美托洛尔5 /每天一次50毫克（Logimax，Mobloc，Astra）或依那普利10毫克每天一次。如果4周后血压（BP）仍未达到最佳控制水平（给药后24小时仰卧舒张压BP> 90 mm Hg），则剂量应再增加一倍，持续4周。 8周后，非洛地平-美托洛尔降低的仰卧血压明显高于依那普利（分别为19.7 / 12.0 mmHg和11.1 / 7.2 mm Hg）。治疗之间的血压变化的平均差异为8.6 / 4.8 mm Hg，而使用非洛地平-美托洛尔（P = 0.001 / P <0.001）。在站立的BP患者中，非洛地平-美托洛尔的优势也有统计学上的显着差异。即使在依那普利组中增加剂量的患者（61％）比非洛地平-美托洛尔组增加剂量（40％），依那普利治疗的患者获得了足够的血压控制（41％vs非洛地平-63％）美托洛尔，P <0.05）。两种治疗均耐受良好。非洛地平-美托洛尔治疗的三例患者和依那普利治疗的四例因不良事件而中止治疗。每个治疗组中有相似数量的患者报告了不良事件。综上所述，非洛地平-美托洛尔5 / 50-10 / 100 mg每日一次的组合片剂在给药后24小时比依那普利10-20 mg每天一次更有效地降低血压。结果是可以预期的，但更重要的观察结果是两种疗法的耐受程度相似。显然，可以很好地耐受血压的明显降低，这是本研究证明的主要目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号